Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 3/20 | 0.46 |
| ▸ | CA7 | P43166 | 3/20 | 0.46 |
| ▸ | CA9 | Q16790 | 3/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.46 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.46 |
| ▸ | CA4 | P22748 | 2/20 | 0.46 |
| ▸ | CA6 | P23280 | 2/20 | 0.46 |
| ▸ | CA5A | P35218 | 2/20 | 0.46 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.46 |
| ▸ | TTR | P02766 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | FPR2 | P25090 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16607262 | 0.90 | LMNA (0.52) | LMNACA12CA7CA9CA14 | |
| SCHEMBL17889248 | 0.83 | FPR2 (0.43) | LMNAMEN1KMT2AALDH1A1FPR2 | |
| SCHEMBL17889247 | 0.83 | FPR2 (0.43) | LMNAMEN1KMT2AALDH1A1FPR2 | |
| SCHEMBL20558910 | 0.81 | OPRD1 (0.48) | LMNACA12CA7CA9CA14 | |
| SCHEMBL16607361 | 0.80 | LMNA (0.47) | LMNACA12CA7CA9CA14 | |
| SCHEMBL4230415 | 0.76 | FPR2 (0.46) | LMNAALDH1A1FPR2CREBBPESR1 | |
| SCHEMBL15765005 | 0.74 | CA12 (0.44) | LMNACA12CA7CA9CA14 | |
| SCHEMBL20083706 | 0.74 | ESR1 (0.67) | LMNAALDH1A1ESR1 | |
| SCHEMBL18106169 | 0.74 | FDPS (0.41) | LMNACA12CA7CA9CA14 | |
| SCHEMBL17889259 | 0.74 | FPR2 (0.42) | NPC1RAB9AHCAR2ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3511003-B1 | CYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | TORAY INDUSTRIES (JP) | 2021-03-03 | — | — | EP | disclosed |
| EP-3511002-B1 | CYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | TORAY INDUSTRIES (JP) | 2020-08-19 | — | — | EP | disclosed |
| EP-3050877-B1 | CYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | TORAY INDUSTRIES (JP) | 2019-10-30 | — | — | EP | disclosed |
| EP-3511003-A1 | CYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | Toray Industries, Inc. (JP) | 2019-07-17 | — | — | EP | disclosed |
| EP-3511002-A1 | CYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | Toray Industries, Inc. (JP) | 2019-07-17 | — | — | EP | disclosed |
| US-20180104221-A1 | CYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | TORAY INDUSTRIES, INC. (JP) | 2018-04-19 | — | — | US | disclosed |
| US-20180104221-A1 | CYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | TORAY INDUSTRIES, INC. (JP) | 2018-04-19 | — | — | US | disclosed |
| US-9505740-B2 | Cyclic amine derivative and pharmaceutical use thereof | TORAY INDUSTRIES, INC. | 2016-11-29 | — | — | US | disclosed |
| US-9505740-B2 | Cyclic amine derivative and pharmaceutical use thereof | TORAY INDUSTRIES, INC. | 2016-11-29 | — | — | US | disclosed |
| WO-2016152955-A1 | CYCLIC AMINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | 東レ株式会社 | 2016-09-29 | — | — | WO | disclosed |
| US-20160194302-A1 | CYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | TORAY INDUSTRIES, INC. (JP) | 2016-07-07 | — | — | US | disclosed |
| US-20160194302-A1 | CYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | TORAY INDUSTRIES, INC. (JP) | 2016-07-07 | — | — | US | disclosed |
| WO-2015046403-A1 | CYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | 東レ株式会社 | 2015-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160194302-A1 | CYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | CNR2, OPRL1, CNR1 | LMNA 2892/4885CA12 1348/4885CA7 753/4885 |
| US-20180104221-A1 | CYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | OPRL1, CNP, AANAT | LMNA 2593/4885CA12 3529/4885CA7 2670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.